Post-stroke Hyperglycemia in Non-diabetic Ischemic Stroke is Related With Worse Functional Outcome: A Cohort Study

Abstract

Objective

To investigate long-term and serial functional outcomes in ischemic stroke patients without diabetes with post-stroke hyperglycemia.

Methods

The Korean Stroke Cohort for Functioning and Rehabilitation (KOSCO) is a large, multi-center, prospective cohort study of stroke patients admitted to participating hospitals in nine areas of Korea. From KOSCO, ischemic stroke patients without diabetes were recruited and divided into two groups: patients without diabetes without (n=779) and with post-stroke hyperglycemia (n=223). Post-stroke hyperglycemia was defined as a glucose level >8 mmol/L. Functional assessments were performed 7 days and 3, 6, and 12 months after stroke onset.

Results

There were no significant differences in baseline characteristics between the groups, except in the age of onset and smoking. Analysis of the linear correlation between the initial National Institutes of Health Stroke Scale (NIHSS) score and glucose level showed no significant difference. Among our functional assessments, NIHSS, Fugl-Meyer Assessment (affected side), Functional Ambulatory Category, modified Rankin Scale, and Korean Mini-Mental State Examination (K-MMSE) showed statistically significant improvements in each group. All functional improvements except K-MMSE were significantly higher in patients without post-stroke hyperglycemia at 7 days and 3, 6, and 12 months.

Conclusion

The glucose level of ischemic stroke patients without diabetes had no significant correlation with the initial NIHSS score. The long-term effects of stress hyperglycemia showed worse functional outcomes in ischemic stroke patients without diabetes with post-stroke hyperglycemia.

INTRODUCTION

Diabetes is a well-known independent predictor of stroke [1], and the risk of stroke cannot be reduced even in patients with diabetes with well-controlled glucose levels. Excluding patients who are unaware of their diabetes and are not receiving treatment, approximately 20%–50% of acute ischemic stroke patients are hyperglycemic, despite the absence of pre-diagnosed diabetes or impaired glucose tolerance (IGT) [2-4]. An increase in counterregulatory hormones such as glucagon, epinephrine, norepinephrine, and growth hormone enhances hepatic gluconeogenesis and decreases peripheral glucose uptake, thus inducing a hyperglycemic state [5]. Increased cytokine levels in response to stress-related reactions are also considered to cause abnormal increases in the serum glucose levels in acute stroke patents [6].

In human and animal studies, an association was found between stress-induced hyperglycemia and increased cerebral lactate levels, resulting in brain tissue acidosis [7]. Hyperglycemia also adversely affects the ischemic brain by disrupting the blood-brain barrier and accelerating cerebral edema [4], which is associated with impaired cerebrovascular reactivity in the microvasculature upon reperfusion therapy [3]. This phenomenon is known to increase the cerebral infarct size and consequently worsen neurologic outcomes. Magnetic resonance imaging (MRI) was used to demonstrate the loss of penumbra tissue upon elevated glucose levels [8]. Two meta-analyses showed that even mildly elevated glucose levels at admission were associated with a three-fold higher risk of stroke- and myocardial infarction-related mortality, indicating that post-stroke hyperglycemia is a poor prognostic indicator [9,10]. The glucose level should be strictly controlled with insulin upon admission to the emergency room in stroke patients since insulin acts directly on the brain parenchyma, which reduces neuronal necrosis in the cortex, striatum, and hippocampus [11,12].

Intensive rehabilitation can enhance functional improvements after hemorrhagic stroke as patients with stress hyperglycemia had lower scores on all functional assessments during all time points among patients with subarachnoid hemorrhage (SAH) [13]. The long-term functional outcomes of patients with ischemic stroke have not yet been established. A prospective cohort study, in conjunction with the Korean Stroke Cohort for Functioning and Rehabilitation (KOSCO), was conducted to investigate the long-term and serial functional outcomes of ischemic stroke patients without diabetes and with post-stroke hyperglycemia.

MATERIALS AND METHODS

Study design

KOSCO is a large, multi-center, prospective cohort study of all first-time acute stroke patients admitted to participating hospitals in nine distinct areas of Korea. This 10-year longitudinal follow-up study investigates the residual effects, activity limitations, and quality of life of first-time stroke patients.

Ethics statement

The research was approved by the Research Ethics Committee of Pusan National University Yangsan Hospital (No. 05-2012-057). Written informed consent was obtained from all patients prior to the study. If the patient was unable to provide consent, it was obtained from the patient’s legal representative.

Study subjects

All patients with first-time acute stroke admitted to the study hospitals were asked to participate. The inclusion criteria were: (1) first-time acute ischemic stroke, including supratentorial and infratentorial lesions, with corresponding evidence of acute arterial occlusion on computed tomography/CTA (computed tomography angiography) or MRI/MRA (magnetic resonance angiography); (2) age ≥19 years at stroke onset. Acute stroke was defined as a rapidly evolving, focal neurological deficit persisting for >24 hours. The exclusion criteria were: (1) recurrent stroke, (2) history of transient ischemic attack, (3) traumatic/non-traumatic intracerebral hemorrhage, (4) a diagnosis of diabetes before admission, (5) uncontrolled diabetes before stroke onset—glycated hemoglobin (HbA1c) level (≥6.2%) [14]; (6) unknown medical history; (7) other associated major illnesses such as myocardial infarction; and (8) pulmonary embolism or active infection as confirmed by radiologic or laboratory studies.

Procedure

All eligible patients were recruited at the time of stroke evaluation. Patient enrollment was planned over a 3–4 year period. The patients were enrolled in the study after written informed consent was obtained from the patients or their legal representatives.

Baseline review of medical records

A complete enumeration survey of all patients was performed for the baseline using a review of the medical records on the first admission. The presence of cerebrovascular risk factors was assessed using standardized, structured questionnaires and classified according to the current guidelines of the American Heart Association [15]. Comorbidities were assessed using the Charlson Comorbidity Index [16]. Initial stroke severity was recorded at the time of hospital arrival using the National Institutes of Health Stroke Scale (NIHSS) for ischemic strokes [17].

Neuroimaging was performed on all patients; CTA, MRA, or ultrasonography according to the standards of clinical practices. Etiology was based on neuroimaging, medical history, and medication use; the TOAST (Trial of ORG 10172 in Acute Stroke Treatment) classification was used to categorize the etiologies [18].

Post-stroke hyperglycemia was defined as a randomly tested glucose level >8 mmol/L (144 mg/dL) upon admission [9,19]. The HbA1c levels were assessed to rule out previously undiagnosed diabetes and IGT. In total, 1,002 patients fulfilled the criteria based on the baseline data gathered in August 2012. These patients were divided into two groups: patients without diabetes without (n=779) and with stress hyperglycemia (n=223).

Follow-up

A two-step approach was used on all patients for follow-up assessment. First, they were contacted by telephone. If this approach failed, a second telephone call was made to contact the patients’ caregivers. Information on the patients’ status was obtained through these telephone interviews. All living patients were invited to visit the research center for functional assessments, structured self-administered questionnaires, and face-to-face interviews. If the patients were unable to visit the research center, the investigations were performed in their homes. The primary caregivers visited our researchers for structured self-administered questionnaires and face-to-face interviews.

Functional assessments

Baseline

Baseline evaluation was performed 7 days after stroke onset using face-to-face functional assessments, including the Korean version of NIHSS (K-NIHSS) for stroke severity [17], Korean Mini-Mental State Examination (K-MMSE) for cognitive function [20], Fugl-Meyer Assessment (FMA) for motor function [21], Functional Ambulatory Category (FAC) for mobility and gait [22], and the modified Rankin Scale (mRS) for general functional assessment [23].

Follow-up

All patients were evaluated using face-to-face functional assessments, which were performed at 3, 6, and 12 months post-discharge. The measures of outcomes, baseline, and Functional Independence Measure (FIM) utilized the same batteries [24], and a Korean version of the modified Barthel Index (K-MBI) [25] were added for activities of daily living (ADL) assessment. All functional assessments were conducted as blind evaluations by the same occupational therapist.

Statistical analysis

Statistical analysis was performed using SPSS for Windows version 21.0 (IBM, Armonk, NY, USA). Descriptive statistics and frequency, crosstabs, and chi-square distribution analyses were used to compare data obtained from the baseline review of medical records and initial stroke characterization. Scale factors were analyzed using descriptive statistics and an independent t-test. One-way ANOVA was used to analyze the functional outcome variation over time in each group. Generalized estimating equations (GEE) were used after correcting for age, sex, and initial NIHSS score to find the intergroup difference of functional improvement by stress hyperglycemia. p<0.05 was considered significant.

RESULTS

Initially, 1,084 patients enrolled in our study, with a final sample size of 1,002 patients. The follow-up rate was 7.7% (n=84) due to incomplete follow up. Among the 1,002 patients, 779 (78%) and 223 (22%) had an initial serum glucose level less than and greater than 8 mmol/L (144 mg/dL), respectively (Fig. 1).

Fig. 1.

Flow diagram of this study. KOSCO, Korean Stroke Cohort for Functioning and Rehabilitation; IGT, impaired glucose tolerance; HbA1c, glycated hemoglobin.

On comparing the baseline characteristics, age of onset and smoking habits showed significant differences between the groups (p<0.05). There were no significant differences in the body mass index; waist circumference; and stroke risk factors such as hypertension, atrial fibrillation, hyperlipidemia, family history, and alcohol consumption history. There was also no significant difference in the types of ischemic stroke, initial NIHSS scores, and hospital arrival time between the groups (Table 1).

Table 1.

Baseline characteristics according to stress hyperglycemia of stroke patients

Parameter		Total (n=1,002)	Non-diabetics without post-stroke hyperglycemia (n=779)	Non-diabetics with post-stroke hyperglycemia (n=223)	p-value
Sex, male		606 (60.5)	481 (61.7)	125 (56.1)	0.125a)
Age (yr)		67.51±13.04	67.07±13.38	69.02±11.65	0.034c)
BMI (kg/m2)		23.42±3.00	23.38±2.94	23.55±3.24	0.471c)
Waist circumference (cm)		82.83±8.69	82.69±8.40	83.42±9.88	0.485c)
Risk factors of stroke
	Hypertension	504 (50.3)	386 (49.6)	118 (52.9)	0.376a)
	Coronary heart disease	36 (3.6)	35 (4.5)	4 (1.8)	0.167a)
	Atrial fibrillation	84 (8.4)	82 (10.6)	22 (9.9)	0.457a)
	Hyperlipidemia	129 (12.9)	99 (12.7)	30 (13.5)	0.770a)
	Unruptured intracranial aneurysm	5 (0.5)	5 (0.6)	0 (0.0)	0.593b)
	Obesity	97 (9.7)	78 (10.0)	19 (8.5)	0.607a)
	Family history	79 (7.9)	66 (8.5)	13 (5.8)	0.197a)
Smoking					0.040a)
	Current smokers	297 (29.6)	244 (31.3)	53 (23.8)
	Former smokers	113 (11.3)	91 (11.7)	22 (9.9)
	Never smokers	592 (59.1)	444 (57.0)	148 (66.4)
Alcohol consumption					0.242a)
	None	625 (62.4)	496 (63.7)	129 (57.8)
	Moderate	256 (25.5)	190 (24.4)	66 (29.6)
	Heavy	121 (12.1)	93 (11.9)	28 (12.6)
Ischemic type (TOAST)					0.307a)
	Large-artery atherosclerosis	472 (47.1)	374 (48.0)	98 (43.9)
	Small-artery occlusion	196 (19.6)	158 (20.3)	38 (17.0)
	Cardioembolism	149 (14.9)	110 (14.1)	39 (17.5)
	Stroke of other determined etiology	73 (7.3)	56 (7.2)	17 (7.6)
	Stroke of undetermined etiology	112 (11.2)	81 (10.4)	31 (13.9)
Ischemic location					0.900c)
	Supratentorial lesion	932 (93.0)	725 (93.1)	207 (92.8)
	Infratentorial lesion	70 (7.0)	54 (6.9)	16 (7.2)
	Hospital arrival time after onset (hr)	4.02±4.39	4.00±4.47	4.10±4.13	0.811c)
	Initial NIHSS score	5.29±5.73	5.17±5.56	5.71±6.31	0.211c)
Initial blood parameter
	Glucose (mg/dL)	128.06±38.1	113.08±15.60	180.39±46.60	0.000c)
	Total cholesterol (mg/dL)	177.48±51.3	176.54±52.00	180.74±48.70	0.282c)

Values are presented as number (%) or mean±standard deviation.

BMI, body mass index; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; NIHSS, National Institutes of Health Stroke Scale.

^a)Chi-square test,

^b)Fisher exact test,

^c)independent t-test.

^*p<0.05 (with hyperglycemia patients vs. without hyperglycemia patients).

The degree of serial improvements in extremity functioning and the performance of ADLs were compared. Among our functional assessments, NIHSS, FMA (affected side), FAC, mRS, and K-MMSE, representing stroke severity and motor and cognitive function, showed statistically significant improvements at 7 days and 3, 6, and 12 months in the two groups (p<0.05).

All functional assessments, excluding K-MMSE, showed worse scores in patients with post-stroke hyperglycemia than in patients without post-stroke hyperglycemia at 7 days and 3, 6, and 12 months (p<0.05). The NIHSS score at 12 months in patients with post-stroke hyperglycemia showed regression from 2.72±5.77 to 3.03±6.00 compared to that at the 6-month assessment (Table 2, Fig. 2).

Table 2.

Comparison of functions of non-diabetics ischemic stroke patients with or without stress hyperglycemia

	Non-diabetics without post-stroke hyperglycemia (n=779)					Non-diabetics with post-stroke hyperglycemia (n=223)					p-value (inter-group)
	7 days	3 months	6 months	12 months	p-value	7 days	3 months	6 months	12 months	p-value
NIHSS	3.54±5.34	2.22±4.33	2.08±4.37	2.05±4.38	0.000*	4.36±6.39	3.00±5.74	2.72±5.77	3.03±6.00	0.000*	0.000*
FMA	82.31±30.70	86.97±26.65	87.31±26.39	87.41±26.63	0.000*	78.63±33.11	84.77±28.58	84.29±29.43	83.22±30.54	0.000*	0.004*
FAC	3.19±1.81	4.13±1.55	4.22±1.52	4.21±1.53	0.000*	2.76±1.98	3.91±1.68	4.06±1.63	3.98±1.72	0.000*	0.000*
mRS	2.33±1.57	1.52±1.50	1.42±1.50	1.36±1.52	0.000*	2.61±1.55	1.74±1.55	1.62±1.55	1.69±1.61	0.000*	0.000*
K-MMSE	21.73±9.20	23.50±8.46	23.74±8.41	23.72±8.73	0.000*	20.50±10.21	22.91±8.90	23.57±8.20	23.04±8.81	0.000*	0.051
K-MBI	-	86.63±26.17	87.24±26.72	87.72±26.59	0.057	-	82.86±29.24	84.07±29.16	83.84±30.35	0.183	0.004*
FIM	-	109.40±28.28	110.23±28.51	110.54±28.86	0.045	-	105.09±31.49	106.76±31.18	106.44±32.13	0.563	0.007*

Values are presented as mean±standard deviation.

NIHSS, National Institutes of Health Stroke Scale; FMA, Fugl-Meyer Assessment (affected side); FAC, Functional Ambulation Categories; mRS, modified Rankin Scale; K-MMSE, Korean Mini-Mental State Examination; K-MBI, Korean version of Modified Barthel Index; FIM, Functional Independence Measure.

^*p<0.05.

Fig. 2.

Comparison of (A) National Institutes of Health Stroke Scale (NIHSS) and (B) modified Rankin Scale (mRS) between the group with or without post-stroke hyperglycemia in non-diabetic ischemic stroke patients.

DISCUSSION

Glucose concentrations in the blood are regulated through hormonal, neural, and hepatic autoregulatory mechanisms in healthy individuals without diabetes. Illness, however, may alter normal human physiology, leading to the increased production of counter-regulatory hormones, leading to a hyperglycemic state [6]. Stress-induced hyperglycemia causes acidosis in the brain parenchyma, which negatively affects mitochondrial function in the penumbra and increases the cerebral infarct size [9]. A systematic review showed that, in patients with no history of diabetes presenting with ischemic stroke, moderately elevated glucose levels were associated with three-fold higher mortality and an increased risk of poor functional recovery [10]. Among patients with acute ischemic stroke, those with hyperglycemia upon hospital admission had a significantly higher risk of death within 30 days, 1 year, and 6 years post-stroke [26].

The limitations of previous studies include a differing definition of post-stroke hyperglycemia, thus leading to questions concerning the reliability of the results. The other limitations were the inclusion of subjects with hemorrhagic stroke as well as undiagnosed diabetes or IGT; moreover, limited outcome assessment tools were used due to a focus on mortality.

In our study, we conducted random glucose assessments at the time of admission in a consistent manner and applied reference values based on a previous study (>8 mmol/L or >144 mg/dL) [18]. Analysis was performed on first-time ischemic stroke patients without diabetes, excluding patients with hemorrhagic stroke. Since the two groups showed no difference in the etiological distribution according to the TOAST classification, the prognosis according to the etiology should have no effect on the outcomes. HbA1c is the most reliable parameter used exclude patients with poor glucose control; this has also been used in previous studies [10]. The enrolled patients had less severe clinical conditions and were able to participate in the serial functional assessments. None of our patients expired during the follow-up period.

A study showed that blood glucose has no effect on the amount of hemispheric brain swelling or infarct size after middle cerebral artery occlusion in rats [27]. Our study found no significant differences in the NIHSS scores at the time of admission between the two groups, indicating that post-stroke hyperglycemia does not affect the penumbra. The mean glucose-check time from onset were 4.00±4.47 and 4.10±4.13 hours for patients without and with hyperglycemia, respectively (p>0.05). The importance of strict and prompt control of glucose after the onset of stroke to prevent additional brain damage is emphasized.

Patients with stress hyperglycemia showed lesser improvements in stroke severity, cognitive function, motor function, mobility and gait, and general functional assessment in the short- to long-term follow-up. Although the initial NIHSS scores showed no significant differences between the two groups (5.17±5.56 and 5.71±6.31 for patients without and with hyperglycemia, respectively), it is interesting to note that the NIHSS scores showed a regression from 2.72±5.77 to 3.03±6.00 at 12 months in patients with post-stroke hyperglycemia compared to the values at the 6-month assessment. The long-term functional outcomes of ischemic stroke patients without diabetes showed significant differences between the groups with or without post-stroke hyperglycemia.

Our study emphasized the long-term effects of post-stroke hyperglycemia on patients’ ADLs. The mechanism underlying how it increases the severity of brain injuries is already known. Although the initial NIHSS scores had no significant differences, this study proved this mechanism on long-term follow-up.

One of the limitations of our study is that the interpretation of post-stroke hyperglycemia is not fixed. Since a single-time measurement of a random glucose level at admission was used, the cut-off level used to define hyperglycemia might differ from that used in other studies, in which the fasting glucose level the morning after admission ranged from 6.1–7.8 mmol/L (110–141 mg/dL). Patients with borderline glucose levels might have a ceiling effect [28-31].

Volumetric analysis by CT/CTA or MRI/MRA scans may be valuable to investigate and compare the severity of stroke between the groups. A study mentioned that assuming glucose was controlled after admission, monitoring for post-stroke hyperglycemia continuously may be a superior approach since it is associated with worse outcomes [32].

In conclusion, the glucose levels of ischemic stroke patients without diabetes had no significant correlation with the initial NIHSS score. The long-term effects of stress hyperglycemia showed worse functional outcomes in ischemic stroke patients without diabetes with post-stroke hyperglycemia.